Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

0.7150
-0.0008-0.11%
Post-market: 0.71970.0047+0.66%16:43 EDT
Volume:95.83K
Turnover:69.33K
Market Cap:2.41M
PE:-0.05
High:0.7400
Open:0.7400
Low:0.7055
Close:0.7158
52wk High:480.00
52wk Low:0.7055
Shares:3.37M
Float Shares:3.37M
Volume Ratio:0.94
T/O Rate:2.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.8013
EPS(LYR):-303.4772
ROE:-106.98%
ROA:-53.08%
PB:0.19
PE(LYR):0.00

Loading ...

Clearmind names Hila Kiron-Revach board chair after Amitay Weiss steps down

Reuters
·
May 01

Clearmind evaluates MEAI for FDA breakthrough therapy designation in alcohol use disorder trial

Reuters
·
Apr 27

Clearmind Medicine Inc - Has Not Submitted or Received FDA Breakthrough Therapy Designation for Meai

THOMSON REUTERS
·
Apr 27

Clearmind Medicine issues $2.7 million convertible notes at 10% discount

Reuters
·
Apr 21

Clearmind welcomes Trump executive order speeding FDA review of breakthrough psychedelic therapies

Reuters
·
Apr 21

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM

Reuters
·
Apr 20

Clearmind says CMND-100 meets primary safety endpoint in AUD Phase I/IIa trial

Reuters
·
Apr 20

Clearmind Medicine Inc - Cmnd-100 Shows High Safety Profile at Highest Dosage With No Serious Adverse Events

THOMSON REUTERS
·
Apr 20

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

GlobeNewswire
·
Apr 20

Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial

TIPRANKS
·
Apr 16

Clearmind announces DSMB recommendation to continue CMND-100 trial

TIPRANKS
·
Apr 16

Clearmind advances CMND-100 alcohol use disorder trial, raises dose to 160 mg

Reuters
·
Apr 15

Clearmind Medicine Inc - Cmnd-100 Well Tolerated With No Serious Adverse Events in Third Cohort

THOMSON REUTERS
·
Apr 15

Clearmind Medicine Inc - to Proceed to Fourth Cohort, Increase Cmnd-100 Dose to 160Mg

THOMSON REUTERS
·
Apr 15

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in Ongoing Cmnd-100 Clinical Trial

THOMSON REUTERS
·
Apr 15

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial

GlobeNewswire
·
Apr 15

Clearmind Medicine issues $1.75 million convertible notes, raises $1.58 million cash

Reuters
·
Apr 15

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere

Reuters
·
Apr 14

BUZZ-Clearmind Medicine rises after alcohol addiction drug shows safety in early trial

Reuters
·
Apr 14

Clearmind Medicine Inc - Third Cohort Results Show High Safety Profile for Cmnd-100 With No Serious Adverse Events

THOMSON REUTERS
·
Apr 14